'Vegfr 2' diaporamas de présentation

New Cancer Therapies Based on Thyrosine Kinase Inhibitors Axel Ullrich

847 views • 75 slides

776 views • 42 slides

424 views • 42 slides

VEGF inhibitors: predictive markers and biological insights

566 views • 38 slides

Compensatory Angiogenesis and Tumor Refractoriness

Compensatory Angiogenesis and Tumor Refractoriness. Prof. Rajesh N Gacche Tumor Biology Laboratory, School of Life Sciences SRTM Univeristy , Nanded , India (MS). Angiogenesis is the formation of new blood vessels from preexisting one. Structure of vessels and capillaries. Small artery:.

463 views • 34 slides

Adjuvant systemic therapy in breast cancer

530 views • 33 slides

Biomarker for Angiogenesis Inhibitors

Biomarker for Angiogenesis Inhibitors. Heinz-Josef Lenz Associate Director, Clinical Research Kathryn Balakrishnan Chair for Cancer Research Co-Director, USC Center for Molecular Pathways and Drug Discovery Co-Leader GI Oncology Program USC/Norris Comprehensive Cancer Center.

510 views • 31 slides

Papel de los nuevos Tki: AXITINIB

575 views • 30 slides

435 views • 22 slides

Background

Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.

357 views • 18 slides

Synthesis, molecular docking studies and cytotoxic screening of certain novel thiazolidinone derivatives substituted wit

Substituted thiazolidinone linked to benzothiazoles and benzoxazoles 3a,b or substituted 5-benzylidene-4- thiazolidinones 4a-h were synthesized. The antitumor activity of the prepared compounds was evaluated against human breast MCF7 and liver HEPG2 cancer cell lines using Sulphorhodamine-B (SRB) assay method, doxorubicin was used as a reference standard. Most of the tested compounds showed potent antitumor activity especially the pmethoxy-5-benzylidine-4-thiazolidinone derivative of benzoxazole 4c and benzothiazole 4d, their IC50 against liver HEPG2 cancer cell line are 0.027 nM and 0.026 nM respectively. The IC50 of p-chloro-5-benzylidine-4- thiazolidinone linked to benzoxazole 4e against breast MCF7 cancer cell line, is 19 nM but, p-nitro-5-benzylidine4-thiazolidinone derivative of benzothiazole 4h showed a broad spectrum antitumor activity against MCF7 and HEPG2 cell lines, its IC50 is 36 and 48 nM respectively. The most active compounds were docked against VEGFR-2 using Moe program and 1Y6A (pdb file) to investigate if these compounds had a similar binding mode to VEGFR-2 inhibitors.

145 views • 10 slides

Supplementary Figure 1

Supplementary Figure 1. HUVEC. A549. ACHN. DU145. kDa. - 150. NRP1. - 102. - 150. NRP2. - 102. - 225. VEGFR-1. - 150. - 225. VEGFR-2. - 150. - 38. GAPDH. - 31. NRP1. GAPDH. Supplementary Figure 2. C. siRNA. C. #4914. #4820. kDa. - 150. - 102. - 38. - 31.

108 views • 3 slides

SIGMA-ALDRICH

Structure of Receptors and Growth Factors Involved in Vasculogenesis, Angiogenesis and Lymphomagenesis. SIGMA-ALDRICH. Structure of Receptors and Growth Factors Involved in Vasculogenesis, Angiogenesis and Lymphomagenesis

219 views • 2 slides

c-Met

c-Met. VEGFR-2.

158 views • 1 slides

Figure 3S (Supplementary Data)

1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 0.81. 0.32. 3.08. 0.39. 2.04. 1.36. 0.29. 0.36. 0.34. 0.40. 0.42. 0.21. 1.14. 0.32. 2.75. 2.57. 0.21. 0.47. 0.28. 0.46. 0.93. 0.24. 0.97. 0.18. A. B. RCC-02-0908. RCC-25-0908.

97 views • 1 slides

PDGF-R ?. p-PDGF-R ? (Tyr1021). Fold. 1 0.8* 0.4** 0.3** 0.1***. p-VEGFR-2(Tyr951). Fold. 1 0.5* 0.3* 0.2** 0.1***. VEGFR-2. p-Gab-1(Tyr627). Fold. 1 0.12* 0.01* 0.01* 0.01*. Gab-1. p-Met(Tyr1003). Fold. 1 0.3* 0.2** 0.1*** 0.1***. c-Met.

111 views • 1 slides